Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · IEX Real-Time Price · USD
12.16
-1.05 (-7.95%)
At close: Jul 2, 2024, 4:00 PM
12.05
-0.11 (-0.90%)
After-hours: Jul 2, 2024, 7:21 PM EDT
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for VRDN stock have an average target of 31.56, with a low estimate of 20 and a high estimate of 40. The average target predicts an increase of 159.54% from the current stock price of 12.16.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VRDN stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +146.71% | Jun 11, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +89.14% | Jun 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +146.71% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $37 → $27 | Strong Buy | Maintains | $37 → $27 | +122.04% | May 9, 2024 |
Financial Forecast
Revenue This Year
353.24K
from 314.00K
Increased by 12.50%
Revenue Next Year
159.12K
from 353.24K
Decreased by -54.95%
EPS This Year
-3.78
from -5.31
EPS Next Year
-3.98
from -3.78
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.1M | 1.1M | 731.8M | 1.5B | 1.9B |
| Avg | 353,236 | 159,120 | 116.9M | 468.6M | 814.7M |
| Low | 70,560 | n/a | n/a | 166.9M | 306.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 568.8% | 197.3% | 459,798.2% | 1,180.8% | 297.8% |
| Avg | 12.5% | -55.0% | 73,354.0% | 300.9% | 73.8% |
| Low | -77.5% | - | - | 42.8% | -34.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.09 | -2.87 | 4.27 | 11.37 | 12.55 |
| Avg | -3.78 | -3.98 | -2.92 | -0.03 | 2.83 |
| Low | -4.32 | -4.83 | -4.64 | -2.73 | -0.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.